Cochrane · systematic review · CD015122
Tranexamic acid for percutaneous nephrolithotomy
Cleveland, B, Norling, B, Wang, H, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
16
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 11.1%Very low 1 · 5.6%Low 8 · 44.4%Moderate 7 · 38.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Systemic TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy
Population: percutaneous nephrolithotomy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Blood transfusion Systemic TXA vs No TXA (placebo or usual care) | RR 0.45 [0.27, 0.76] | 9 studies · 1353 participants | Moderate Downgraded: risk of bias |
Stone‐free rate Systemic TXA vs No TXA (placebo or usual care) | RR 1.11 [0.98, 1.27] | 4 studies · 603 participants | Low Downgraded: risk of bias |
Thromboembolic events Systemic TXA vs No TXA (placebo or usual care) | 0 | 6 studies · 841 participants | Moderate Downgraded: risk of bias |
Adverse events Systemic TXA vs No TXA (placebo or usual care) | RR 5.22 [0.52, 52.72] | 4 studies · 602 participants | Low Downgraded: risk of bias |
Secondary interventions Systemic TXA vs No TXA (placebo or usual care) | RR 1.15 [0.84, 1.57] | 2 studies · 319 participants | Low Downgraded: risk of bias |
Major surgical complications Systemic TXA vs No TXA (placebo or usual care) | RR 0.36 [0.21, 0.62] | 5 studies · 733 participants | Moderate Downgraded: risk of bias |
Minor surgical complications Systemic TXA vs No TXA (placebo or usual care) | RR 0.71 [0.45, 1.1] | 5 studies · 733 participants | Low Downgraded: risk of bias |
Unplanned hospitalizations or readmissions Systemic TXA vs No TXA (placebo or usual care) | RR 1.55 [0.45, 5.31] | 1 study · 189 participants | Very low Downgraded: risk of bias |
Hospital length of stay Systemic TXA vs No TXA (placebo or usual care) | no estimate extracted | 7 studies · 1151 participants | Low Downgraded: risk of bias |
Topical TXA compared to No TXA (placebo or usual care) for percutaneous nephrolithotomy
Population: Percutaneous nephrolithotomy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Blood transfusion Topical TXA vs No TXA (placebo or usual care) | RR 0.4 [0.2, 0.81] | 1 study · 400 participants | Moderate Downgraded: risk of bias |
Stone‐free rate Topical TXA vs No TXA (placebo or usual care) | RR 1.07 [0.99, 1.17] | 1 study · 400 participants | Low Downgraded: risk of bias |
Thromboembolic events Topical TXA vs No TXA (placebo or usual care) | RD 0 | 1 study · 400 participants | Moderate Downgraded: risk of bias |
Adverse event Topical TXA vs No TXA (placebo or usual care) | RD 0 | 1 study · 400 participants | Moderate Downgraded: risk of bias |
Secondary interventions Topical TXA vs No TXA (placebo or usual care) | no estimate extracted | 0 studies · 0 participants | Ungraded |
Major surgical complications Topical TXA vs No TXA (placebo or usual care) | RR 0.69 [0.45, 1.06] | 1 study · 400 participants | Low Downgraded: risk of bias |
Minor surgical complications Topical TXA vs No TXA (placebo or usual care) | RR 0.73 [0.59, 0.91] | 1 study · 400 participants | Low Downgraded: risk of bias |
Unplanned hospitalizations or readmissions Topical TXA vs No TXA (placebo or usual care) | no estimate extracted | 0 studies · 0 participants | Ungraded |
Hospital length of stay Topical TXA vs No TXA (placebo or usual care) | no estimate extracted | 1 study · 400 participants | Moderate Downgraded: risk of bias |